Bolt Biotherapeutics Faces Nasdaq Delisting Warning

TL;DR

Nasdaq's kicking Bolt out, they gotta fix it or get booted.

AI Summary

Bolt Biotherapeutics, Inc. announced on January 2, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is currently evaluating its options and plans to regain compliance.

Why It Matters

This filing signals potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — Failure to meet listing requirements and potential delisting poses a significant risk to the company's market presence and investor base.

Key Players & Entities

• Bolt Biotherapeutics, Inc. (company) — Registrant
• Nasdaq Stock Market (company) — Listing Exchange
• January 02, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share BOLT The Nasdaq Global Se
• $1.00 b — common stock no longer met the minimum $1.00 bid price per share requirement for conti
• $1.00 — Company's common stock must be at least $1.00 per share for a minimum of 10 consecuti

Filing Documents

• bolt-20250102.htm (8-K) — 40KB
• 0000950170-25-001159.txt ( ) — 155KB
• bolt-20250102.xsd (EX-101.SCH) — 25KB
• bolt-20250102_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on July 2, 2024, the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notified Bolt Biotherapeutics, Inc. (the "Company") that, based on the previous 30 consecutive business days, its common stock no longer met the minimum $1.00 bid price per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). Therefore, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until December 30, 2024, to regain compliance. As the Company did not regain compliance with the Minimum Bid Requirement by December 30, 2024, the Company applied to transfer the listing of its common stock to The Nasdaq Capital Market, as allowed under Nasdaq Listing Rule 5810(c)(3)(A), in order to qualify for an additional 180 calendar days to regain compliance. On January 2, 2025, the Company received written notice from Nasdaq notifying the Company that its application to transfer the listing of its common stock to The Nasdaq Capital Market was approved. The approval is based upon the Company meeting the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the Minimum Bid Requirement), the Company's written notice of its intention to cure the deficiency by effecting a reverse stock split, if necessary, its agreement to the conditions outlined in the Nasdaq listing agreement, and additional supporting information provided in its application. The Company's common stock will be transferred to The Nasdaq Capital Market at the opening of business on January 6, 2025, and the Company will be granted an additional 180 calendar days, or until June 30, 2025, to regain compliance with the Minimum Bid

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bolt Biotherapeutics, Inc. Date: January 3, 2025 By: /s/ William P. Quinn William P. Quinn President, Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR